3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 2a
1
Lung Neoplasms
1
Lung Diseases
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Colonic Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
30
Cisplatin
20
Carboplatin
20
Paclitaxel
18
Dexamethasone
15
Pemetrexed
13
Nivolumab
13
Ipilimumab
12
Fluorouracil
11
Cyclophosphamide
11
Gemcitabine
10
Trastuzumab
9
Docetaxel
9
Cytarabine
9
daratumumab
8
atezolizumab
8
Rituximab
8
Capecitabine
8
Lenalidomide
7
Doxorubicin
7
zanubrutinib
6
Prednisone
6
Daunorubicin
6
Bortezomib
6
venetoclax
5
trametinib
5
nilotinib
5
ibrutinib
5
fludarabine
5
dabrafenib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Has announcements
×
pralsetinib
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA